8-K

iBio, Inc. (IBIO)

8-K 2022-11-03 For: 2022-11-03
View Original
Added on April 07, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 3, 2022

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

001-35023 26-2797813
(Commission File Number) (IRS Employer Identification No.)

8800 HSC Parkway

Bryan , Texas **** 77807

(Address of principal executive offices and zip code)

( 979 ) 446-0027

(Registrant’s telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per share IBIO NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

iBio, Inc. (the “Company”) has updated its corporate presentation. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
--- ---

Exhibit 99.1 is furnished with this Current Report on Form 8-K.

Exhibit<br>Number Exhibit Description
99.1 Corporate Presentation of iBio, Inc. dated November 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 3, 2022 IBIO, INC.
By: /s/ Thomas F. Isett
Name: Thomas F. Isett
Title: Chief Executive Officer

Exhibit 99.1

November 2022<br><br><br> © iBio, Inc., All Right Reserved
Forward-looking statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this presentation. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to obtain regulatory approvals for commercialization of its product candidates, including IBIO-101, or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its ability to retain its key employees or maintain its NYSE American listing, and the other factors discussed in the Company’s most recent Annual Report on Form 10-K and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this presentation is provided only as of today, and we undertake no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
---
The high failure rate of targets derived from traditional drug discovery methods contribute to the high cost of developing new therapies Industry Benchmarks to Reach IND1 Failure Rate >99% Time >3 Years Cost >$20-60M2<br>1<br>https://<br>www.researchgate.net/publication/265288848_The_Global_Biomedical_Industry_Preserving_US_Leadership;<br><br>2<br><br>Morgan<br><br>et<br><br>al,<br><br>Nature<br><br>Reviews<br><br>Drug<br><br>Discovery<br><br>2018<br><br><br>DRUG<br><br>DISCOVERY<br><br>PRECLINICAL<br><br>CLINICAL<br><br>TRIAL<br><br>~5,000<br><br><br><br>10,000<br>COMPOUNDS<br><br>250<br><br><br>3<br>-<br>6<br><br>YEARS
---
Antibody engineering is hard: drug programs often fail due to the inability of molecules to selectively bind to disease-causing cells vs. healthy ones Antibodies are built from stretches of amino acids, which are the words and sentences that make up the natural language of biology. We are using AI to decipher that language with a goal to create immunotherapies directed toward hard-to-drug targets.<br> AI-powered precision-targeting GEN 3 Greater potency GEN 2 Enabling next-gen formats GEN 1
---
hard<br>-<br>to<br>-<br>drug<br><br>targets<br><br> Leveraging AI-powered discovery engine to develop precision antibody candidates against<br> AI-powered RubrYc® Discovery Engine<br> Pipeline against hard-to-drug targets Growing pipeline with immuno-oncology focus<br><br> Execution<br>Treg depleting anti-CD25<br><br>PD-1 agonist<br>Tumor-selective EGFRvIII<br>Targeted CCR8 mAb<br>Added 6 pipeline<br>candidates in first 6 months<br>Platform<br><br>capability<br>advancing<br>Successful<br><br>advancement<br>of 3 assets in last 3 months
---
Our AI-driven RubrYc® Discovery Engine tech stack<br><br> Epitope 1 Engineering Engine • Proprietary epitope steering for challenging targets and MoAs • AI-engineered epitope preserves target structure Antibody Library Antibody 3 Optimizer • Fully human sequences • Uses clinically validated antibody frameworks • AI-optimized mammalian display format for downstream developability • Generates functionally-enriched library from template antibody • A fraction of the time of traditional lead optimization Proprietary epitope steering and an advanced library consistently delivers hits on difficult targets<br><br>2
---
RubrYc<br><br>AI<br>-<br>generated<br><br>naïve<br><br>antibody<br><br><br><br>Epitope Engineering<br><br>Engineered<br><br><br>Optimizer<br><br><br><br><br><br><br><br> The RubrYc Discovery Engine in action<br><br><br><br><br><br><br><br><br><br><br> AI-powered precision targeting of conformational & sub-dominant epitopes Epitope-specific antigens built to efficiently & selectively discover antibodies Epitope-specific mAbs processed through<br>screening funnels to identify hits AI-powered sequence optimization to improve performance Optimized Leads<br>evaluated & ranked in translational<br>disease models<br>Patents<br><br>pending
---
Therapeutics pipeline growth and maturation driven primarily by cancer immunotherapies developed with the RubrYc Discovery Engine<br><br><br><br><br>Fibrosis<br><br>Systemic Scleroderma<br><br><br>Idiopathic Pulmonary<br><br>IBIO-100<br>Fibrotic Diseases<br>Autoimmune Disease<br>PD-1<br>Autoimmune<br><br>Solid Tumors Solid Tumors Immuno-Oncology Immuno-Oncology Immuno-Oncology Immuno-Oncology Immuno-Oncology Immuno-Oncology Immuno-Oncology<br>IBIO-101 Endostatin E4<br><br><br><br><br><br><br><br><br><br>Oncology<br>CLINICAL<br><br>IND<br>-<br>ENABLING<br><br>MIAT<br><br>LEAD<br><br>OPTI<br><br>ION<br><br>EARLY<br><br>DISCOVERY<br><br>LATE<br><br>DISCOVERY<br><br>PROGRAMS
---
Our AI platform powers a focused, capital efficient business plan • Advancing a select few “fast followers” • Licensing and asset sales for other molecules<br> • Partner existing molecules or discovery projects against new<br>targets • Potential for upfront, milestone<br>payments and/or royalties<br><br>Proprietary<br>pipeline<br><br>RubrYc<br>Discovery<br>Platform<br><br>Discovery<br>partnerships
---
IBIO-101 IL-2 sparing anti-CD25<br><br><br><br><br><br><br> 10
---
IBIO-101 for regulatory T-cell (Treg) depletion<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br> *Roche acquisition of Tusk Therapeutics completed for €70M upfront, acquiring worldwide rights to anti-CD25 program. Values converted to dollars as reported in public press releases 11<br>IL-2 sparing anti-CD25 antibodies enables depletion of Tregs without affecting Teffs<br>Fast-follower to the one other similar molecule in the clinic<br>Differentiation / opportunity<br>Solid tumors<br>Hairy cell leukemia<br>Relapsed mult. myeloma<br>Lymphoma<br>Head & neck cancer<br>Potential indications<br><br>Depletion of immunosuppressive Tregs via antibody dependent cellular<br>cytotoxicity (ADCC),<br>without disrupting activation of effector T-cells (Teffs) in the tumor microenvironment<br>Target mechanism<br>*<br>Roche<br><br>/<br><br>Tusk<br><br>Therapeutics<br><br>(<br>Sep,<br><br>2018)<br><br>$81M upfront,<br>$758M<br><br>total<br><br>deal<br><br>value<br><br>CLINICAL<br><br>PROOF<br><br>OF<br><br>CONCEPT<br><br>CLINICAL<br><br>TESTING<br><br>IND<br><br>PRECLINICAL<br><br>TESTING<br><br>Recent transactions
---
IBIO-101 reduces tumor growth by selectively depleting immuno-suppressive Tregs without affecting cancer killing Teffs 1st gen CD25 mAbs depleted immuno- suppressive Treg and<br>immuno-stimulatory Teff Limited efficacy<br> 2nd gen RTX-003 selectively targets Tregs without blocking IL-2 signaling to Teffs Strong preclinical anti-tumor response<br>1<br>Data<br><br>on<br><br>file.<br><br>Treg<br><br>=<br><br>Regulatory<br><br>T<br><br>Cells;<br><br>Teff<br><br>=<br><br>Effector<br><br>T<br><br>Cells;<br><br>ADCC<br><br>=<br><br>Antibody<br><br>Dependent<br><br>Cellular<br><br>Cytotoxicity<br><br><br>Blocked<br><br>IL<br>-<br>2<br><br>pathways<br><br>IL<br>-<br>2<br><br>Indiscriminate<br>depletion of<br><br><br>CD25<br><br>(IL<br>-<br>2R<br><br>T<br>reg<br>+<br><br>T<br>eff<br><br><br><br><br><br>T<br>reg<br>T<br>eff<br><br>Preferential<br><br>T<br>reg<br><br>depletion<br><br>Natural<br>Killer<br><br>Cell<br><br>IL<br>-<br>2<br><br>signaling<br><br>IL<br>-<br>2<br><br><br><br>eff<br><br><br><br><br><br><br>T<br>reg<br><br>T<br>eff<br><br>ADCC
---
IBIO-101 selectively depletes Tregs iBio-101 potently binds recombinant CD25 while preserving IL-2 signaling which leads to Treg depletion while sparing Teffs<br>RG6292<br><br>Roche’s<br><br>monoclonal<br><br>antibody<br><br>that<br><br>targets<br><br>CD25<br><br>(IL<br>-<br>2R<br>..<br><br>IBIO<br>-<br>101<br><br>is<br><br>Data<br><br>on<br><br>file
---
*<br><br>Significant<br><br>vs<br>hIgG1<br><br>Isotype<br><br>-<br><br>Data<br><br>on<br><br>file.<br><br><br> IBIO-101 increases in Teff/Treg ratio, inhibiting tumor growth Potently increases T-eff/T-reg ratio1 Tumor growth inhibition correlates with T-eff/T-reg ratio<br><br>* Significant vs Negative Control
---
IBIO-101 in combination with a checkpoint inhibitor shows greater efficacy<br> IBIO-101 + PD-1 Checkpoint Inhibitor Enhances Tumor Suppression<br>*hCD25<br><br>animal<br><br>model<br><br>-<br><br>Data<br><br>on<br><br>file.<br><br><br><br><br>* Significant vs Negative Control # Significant vs Anti-PD-1
---
Anti-EGFRvIII High ADCC mAb against tumor-specific EGFRvIII cells<br><br><br><br><br> 16
---
tion<br><br>to<br><br>acquire<br><br>Cullinan<br><br>Oncology’s<br><br>subsidiary,<br><br>Cu<br><br>linan<br><br>Pearl,<br><br>which<br><br>has<br><br>worldw<br><br> EGFRvIII for glioblastoma and other cancers<br> PRECLINICAL TESTING IND CLINICAL TESTING CLINICAL PROOF OF CONCEPT *Seagen / LAVA Therapeutics (Sep. 2022): $50M upfront, $650M in milestones **Taiho / Cullinan Oncology (May 2022): $275M upfront, $130M in milestones<br><br> *Seagen transaction with LAVA Therapeutics was an exclusive license to LAVA- platform. **Taiho transac l ide rights outside of Japan to CLN-081/TAS6417 (EGFR mut<br><br>Binding a tumor- specific mutation of EGFR variant III with an afucosylated antibody for high<br>ADCC.<br><br>EGFRvIII is constantly<br>“switched on” which can lead to the<br>development of a<br>range of different cancers.<br>Target mechanism<br>ant<br><br><br>17<br><br>Glioblastoma<br>Head & neck cancer<br>Non-small cell lung cancer<br>Potential indications<br>Novel EGFRvIII program<br>utiliing an ADCC mechanism, potentially further reducing<br>toxicity & expanding therapeutic window<br>Differentiation / opportunity<br>Recent transactions
---
iBio’s Anti-EGFRvIII mAbs selectively kill EGFRvIII-positive tumor cells and not EGFR1-expressing cells in healthy tissues iBio mAb binding specifically to EGFRvIII Tumor Size Reduction Tumor Size Reduction Non-EGFRvIII specific mAb binds to EGFR1 in skin iBio mAb binding specifically to EGFRvIII iBio mAb doesn’t bind to EGFR1 in skin No skin damage<br>Data<br><br>on<br><br>file<br><br><br><br>iBio’s EGFRvIII-specific mAb exclusively kills cancer cells<br>Non EGFRvIII specific mAbs kill cancer cells but can cause toxicity by binding to EGFR1 in skin cells
---
but not binding wild<br>-<br>type<br>EGFR1<br><br>and thus not affecting<br>healthy cells<br><br>Data<br><br>on<br><br>file<br><br><br> iBio’s EGFRvIII-selective mAbs kill tumor cells without affecting healthy cells iBio EGFRvIII mAbs bind recombinant EGFRvIII which leads to<br>tumor cell killing
---
Anti-CCR8 Highly ADCC anti-CCR8 for the depletion of T-regulatory cells<br><br><br><br><br> 20
---
CCR8 for tumor-infiltrating Treg depletion PRECLINICAL TESTING IND CLINICAL TESTING CLINICAL PROOF OF CONCEPT *Fibrogen / HiFiBio (Jun. & Dec. 2021): $25M option fee, $35M option exercise, $1.1B milestones **Gilead / Jounce (Sep. 2020): $85M upfront, $35M equity investment, $685 clinical, regulatory and commercial milestones *Fibrogen / HiFiBio: Fibrogen purchased option to multiple programs in June 2021, then exercised the option for excl. license to CCR8 program in Dec. 2021. **Gilead / Jounce: Exclusive worldwide license to anti-CCR8 antibody.<br><br>Tumor-infiltrating Tregs highly express CCR8. iBio program targets depletion of highly immunosuppressive<br>CCR8+ Tregs in tumor<br>microenvironment via<br>an ADCC mechanism<br>Target mechanism<br>21<br><br>Broadly applicable in solid tumors<br>Prospective combination<br>therapy<br>Potential indications<br>Selective binding to CCR8<br>over its closely related<br>cousin, CCR4<br>Differentiation / opportunity<br>Recent transactions
---
CCR8+ Treg cells are tumor infiltrating and highly immunosuppressive Depletion of CCR8+ Treg cells has potential to evoke potent tumor immunity<br><br>-<br>520;<br><br>Kidani<br><br><br>CCR8<br><br>&<br><br>CCR4<br><br>non<br>specific<br><br>antibody<br><br>iBio CCR8<br><br>specific antibody<br><br>Intratumor<br><br>cytotoxic<br><br>T<br>-<br>cell<br>activation & tumor death<br>CCR4+ cells spared<br><br>Systemic inflammation<br>Skin toxicity<br>Platelet depletion/aggregation<br>Adverse events<br>CCR4+ cells killed
---
CCR8 antibodies have high-specificity binding and ADCC cell killing High Specificity CCR8 Cell Binding High Specificity & Potent Cell Killing (no ADCC enhanced Fc engineering)<br><br><br><br><br><br><br><br><br> HIGHER CELL BINDING ANTIBODY CONCENTRATION (NM)<br>Data<br><br>on<br><br>file<br><br><br>EC50<br><br>=<br><br>0.098<br><br>nM<br><br>Benchmark<br>EC50<br><br>=<br><br>0.120<br><br>nM<br><br>Strong<br><br>binding<br><br>to<br>CCR8 cells<br><br>Minimal<br><br>binding<br><br>to<br>CCR4 & negative<br>control cells<br><br>iBio<br><br>antibody<br><br>+<br><br>CCR8<br>CCR4<br><br>Negative Controls<br>Secondary<br> antibody<br><br>iBio<br><br>antibody<br><br>+
---
PD-1 agonist Supports restoration of homeostasis for inflammatory diseases<br><br><br><br><br> 24
---
PD-1 Agonist for treatment of inflammatory disorders while preserving low inflammation state in healthy tissue PRECLINICAL TESTING IND CLINICAL TESTING CLINICAL PROOF OF CONCEPT *Gilead / Mirobio (Aug. 2022): Acquired for $405M **Merck / Pandion (Feb. 2021): Acquired for $1.85B<br><br> *Gilead / Mirobo: Mirobio’s lead assets were two checkpoint agonists for autoimmune diseases; most advanced had entered phase 1 **Merck / Pandion: Merch acquired company, including multiple autoimmune assets, lead had completed phase 1a safety study. Preclinical PD-1 agonist was in Pandion pipeline<br><br>Selectively binds PD- 1 without PD-L1/PD- L2 blocking<br>Agonizes PD-1 to suppress of auto- reactive T-cells<br>Target mechanism<br>25<br><br>Inflammatory bowel disease<br>Systemic lupus erythematosus<br>Multiple sclerosis<br>Potential indications<br>Greater safety agonist antibodies known for off-target effects<br>Leverage AI discovery engine<br>to compete among a small number of players<br>Differentiation / opportunity<br>Recent transactions
---
Antagonizing PD-1 with PD-L1 blocking worsens autoimmunity and systemic inflammation Autoimmunity Increased & systemic inflammation<br><br>Strong<br><br>inhibition<br><br>TCR<br><br>MHC<br><br>PD<br>-<br>1<br><br>PD<br>-<br>L1<br><br>presenting<br><br>T-cell<br><br>T<br>-<br>cell<br><br>PD<br>-<br>1<br><br><br><br>Weak<br>T-cell<br>inhibition<br><br>T-cell<br><br>Worsened
---
Agonizing PD-1 without blocking PD-L1 restores activated T-cell suppression<br><br> Autoimmunity Healthy Tissue Low-inflammation preserved Diseased Tissue Reduced inflammation<br><br>Strong<br><br>inhibition<br><br>TCR<br><br>MHC<br><br>Strong<br><br>inhibition<br><br>PD<br>-<br>1<br><br>PD<br>-<br>L1<br><br>presenting<br><br>T<br>-<br>cell<br><br>PD<br>-<br>1<br><br><br><br>Weak<br>T-cell<br>inhibition<br><br>Strong<br><br>inhibition<br><br>Improved
---
In vitro PD-1 agonism equals or surpasses benchmarks and PD-L1<br><br><br>Ab ID<br>EC50<br>(nM)<br>SD-671823 0.88<br>SD-300670 0.31<br>SD-030629 0.36<br>SD-136366 0.28<br>SD-759028 0.52<br>SD-313018 (bispecific) 0.30<br>AnaptysBio<br>APE12095<br>17.4<br>BMS/Celgene<br>PD1AB6<br>0.76<br>IgG1 isotype control inactive<br>Data<br><br>on<br><br>file<br><br><br>SD<br>-<br>1018<br><br>(bispecific<br><br>SD<br>-<br>759028<br><br>SD<br>-<br>1666<br><br><br><br>SD<br>-<br>00670<br><br>SD<br>-<br>67182<br><br>SD<br>-<br>00629<br><br>AnaptysBio<br><br>APE12095<br><br>BMS/Celgene<br><br>PD1AB6<br><br>IgG1<br><br>isotype<br><br>control
---
Primary T-cell suppression equals or surpasses benchmarks and PD-L1<br><br><br><br><br><br><br> 200 Mean of 6 donors IL-2 at 24 hrs.<br> 300<br> Mean of 6 donors CD69 at 72 hrs. 200 100 Anti-HEL IgG1 Isotype Control 100 Anti-HEL IgG1 Isotype Control 0 0<br><br>Data<br><br>on<br><br>file<br><br><br>%<br><br>IL<br>-<br>2<br><br>Release<br><br>CD69<br><br>MFI<br><br>iBio Molecules Benchmark Molecules Natural Agonist
---
In summary<br><br><br><br><br><br><br><br> 30
---
Strong and growing IP estate provides exclusivity for iBio’s pipeline<br><br> 107 Issued Patents (25 U.S.) 35<br>Active Applications (12 U.S.)<br><br><br> Patent protection includes: • Intellectual property (IP) around iBio’s biopharmaceutical candidates • IP related to the RubrYc® Discovery Engine (including Notice of Allowance from USPTO)<br><br><br>More Applications progressing to filing
---
Our leadership team brings drug development & bioprocessing experience<br>Martin Brenner, DVM, Ph.D.<br>CSO<br>Robert Lutz, MBA<br>CFBO<br>Marc Banjak<br>GC<br>Lisa Middlebrook<br>CHRO<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>Tom Isett CEO
---
iBio: Summary<br><br><br> Pipeline of difficult to find biologics • Pipeline of 10 preclinical primarily immuno- oncology (I/O) biologics • Targets have been of interest to major I/O companies • Lead asset is a next- generation anti-CD25 (fast follower to Roche’s RG6292) • Expected to file IND no later than H1 2024 AI-driven discovery platform technology • Own patent-protected platform which uses<br>artificial intelligence engine and proprietary<br>antibody library to discover antibodies that others can’t easily find Preclinical development capability • Preclinical team with a history of quickly and efficiently moving candidates to the<br>clinic • Built >10-product pipeline in 18 months Financial • Ticker: IBIO (NYSE-A); ~9M shares outstanding • In process of selling CDMO facility and business to<br>potentially provide funding for I/O pipeline and platform • Reduced SG&A spend post sale of CDMO; expecting run rate of $2.5-$3.0M per month (~50% of prior rate) • $39.5M of cash/cash<br>equivalents as of 6/30/22 33
---